Congress 2013

Presentations




Lupus in 2050

Autoantibody testing 2050.
Fritzler, Marvin

Autoimmune syndromes induced by adjuvants (ASIA), silicone implants, vaccination, and more-2050.
Shoenfeld, Yehuda



Plenary

2012 Guidelines for management of lupus nephritis.
Hahn, Bevra

Demystifying neuropsychiatric lupus – Is it possible?
Hanly, John G.

Future trials: Less risky?
Merrill, Joan T.

Evidence based induction and maintenance therapy recommendations for lupus nephritis. Use of biologics.
Lightstone, Liz

New treatments for SLE: how were they tested, and how are they used in clinical practice.
van Vollenhoven, Ronald F.

SLE clinical trials. Lessons learned: are all failed trials due to failed treatments?
Furie, Richard

Standard of care of lupus nephritis.
Houssiau, FrÉdÉric A.



Symposium

Basic
Lupus neutrophils NET gain in understanding SLE pathogenesis.
Kaplan, Mariana


Pedriatic
Gonadal function and preservation of reproductive fitness in childhood-onset systemic lupus erythematosus.
Almeida da silva, Clovis A.

Therapy insight: cardiovascular disease in pediatric systemic lupus.
Schanberg, Laura E.

Therapy of lupus nephritis in juvenile patients.
Sandborg, Christy


Epidemiologic
Lessons from lupus epidemiology around the world. Networking in Europe.
Cervera, Ricard

Lessons from lupus epidemiology around the world. The GLADEL experience.
Catoggio, Luis

Lessons from lupus epidemiology: US (LUMINA). 
Alarcon, Graciela S.


Genetic
Genetics of lupus: towards the identification of susceptibility genes in admixed populations with amerindian ancestry.
AlarcÓn-Riquelme, Marta E.

Genetics of SLE: what it means for patients and physicians.
Kimberly, Robert P.

IRF5 & cross-ancestry disease risk.
Harley, John B.



Invited Lecture

Antimalarials revisited.
Ruiz-Irastorza, Guillermo

Biomarkers for lupus: a critical perspective.
Pisetsky, David S.

Derivation and validation of SLICC classification criteria for SLE.
Petri, Michelle

Evidence for treatment of cutaneous lupus: a dermatologist approach.
Werth, Victoria P.

Getting beyond description: explaining the causes of disparities by race/ethnicity in SLE.
Yelin, Edward

Novel insights into diagnosis & treatment of anti-phospholipid syndrome.
Meroni, Pier Luigi

The mosaic of autoimmunity. Infections genetics and autoantibodies.
Shoenfeld, Yehuda

Understanding the challenge of low vitamin D and osteoporosis in lupus.
Pereira, Rosa



Up to Date

Current thinking about prevention, management and outcomes of the neonatal lupus syndromes.
Buyon, Jill

Challenges in the management of OB lupus patients.
Levy, Roger

Lupus and malignancy: the good, the bad, & the unknown.
Clarke, Ann

Lupus biopsy: the nephrologist's point of view.
Lightstone, Liz

Systemic lupus international collaborating clinics: contributions to clinical practice.
Urowitz, Murray



Meet the Professors

Advancing the epidemiologic understanding of lupus with population-based studies: lessons from the Georgia lupus registry (GLR).
Drenkard, Cristina

Arthritis in systemic lupus erythematosus.
Iacobelli, Sergio

CVD risk assessment and treatment. Practical approaches to management.
Manzi, Susan

Developing strategies to address outcome disparities in SLE.
Liang Metthew H.

Does the european perspectives for the management of SLE apply to LA patients. The lupus nephritis experience.
Cervera, Ricard

Improving outcomes in lupus nephritis.
LIGHTSTONELIZ

Issues in pediatric lupus.
Sandborg, Christy

Lupus nephritis.

Ramsey-Goldman, Rosalind

Lupus in adolescents
SÁnchez-Guerrero, Jorge

Management of cutaneous lupus.
Werth, Victoria P.


Management of lupus glomerulonephritis.
Doria, Andrea

Mortality in SLE – 2013.
Urowitz, Murray

Nervous system lupus.
Wallace, Daniel

Neuro-psychiatric SLE.
Barile-Fabris, Leonor A.

Steroids & antimalarials use in lupus.
Ruiz-Irastorza, Guillermo

The myth and reality of CNS involvement in SLE.
SHOENFELD, YEHUDA



The Year in Review

Clinical advances in SLE
Hahn, Bevra

Lupus: the year in review.
Pisetsky, David S.



Oral Presentations

Accuracy of Systemic Lupus International. Collaborating Clinics Classification Criteria applied to Juvenile Systemic Lupus Erythematosus Patients

Adipokines association with clinical, laboratory and medication and its correlation with tnf system in lupus patients. Preliminary analysis.

Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation and Autoantibody Production

Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus

BLyS and APRIL in Lupus Nephritis. A study of candidate biomarkers. Dysregulated phagocytosis in Juvenile Systemic Lupus Erythematosus.

Efficacy and Safety of Rontalizumab (Anti-IFN-Alpha) in SLE Subjects with Restricted Immunosuppressant Use: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.

Final results from an open-label extension study of epratuzumab (SL0006)

Frequency of hematological alterations in patients with SLE and its association with vascular thrombosis. GLADEL Registration.

French registry of immune congenital heart block: Maternal data analysis

High PREDICTS is associated with a 28- fold increased odds for the presence of subclinical atherosclerosis in SLE

Hippocampal atrophy in childhood-onset Systemic Lupus Erythematosus

Impaired Diffusion Tensor Imaging findings in the corpus callosum and cingulum may underlie impaired learning and memory abilities in Systemic Lupus Erythematosus

Interferon-alpha May Impair Endothelial Repair Mechanisms in Patients with SLE

Long-Term Outcomes of Children Born to Women with Systemic Lupus Erythematosus

Lupus Anticoagulant at First Pregnancy Visit is Predictive of Pregnancy Loss in SLE

Mortality Rates among U.S. Medicaid Recipients with SLE, 2000-2006

Neutrophil Gelatinase Associated Lipocalin (NGAL/lipocalin-2) regulates the onset of serum autoantibodies in pristane induced lupus

Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematosus (SLE) in Clinical Practice Settings in the United States

Predictive Atherosclerotic Risk Factors At Inception in a Multicentre, Multinational Cohort

Prevalence and clinical significance of severe infection in patients with systemic lupus erythematosus:preliminary data from RELESSER

Provision of Quality Driven Care In Childhood-onset Systemic Lupus Erythematosus

Renal response to a protein challenge in patients with Lupus Nephropathy and variable degrees of glomerular or intersticial damage after maintenance therap.

Risk Factors for Non-Fatal Cardiovascular Disease in Systemic Lupus Erythematosus: Multivariate Analysis in a Cohort of 306 patients

Risk of nephritis among Danish patients with systemic lupus erythematosus is associated with genetically determined mannose-binding lectin deficiency.

Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 (anti-B7RP-1) in Subjects with Systemic Lupus Erythematosus: Results of a Phase 1 Multicenter, Randomized, Double-blind, Placebo-controlled, Sequential Rising Single-dose Study

Safety, Pharmacokinetics and Pharmacodynamics of AMG 811 (anti-IFN-gamma): Results of a Phase I Single Dose Study in Subjects with Systemic Lupus Erythematosus

SLE18a, a murine 129-derived disease modifier locus on chromosome 3, regulates the expression of Ly108 isoforms in T cells.

SLE Cardiovascular Risk Equation

Study of anti-Müllerian hormone and its relationship to the subsequent probability of pregnancy in 112 patients with SLE, exposed or not to cyclophosphamide.

The granulocyte signature and organ inflammation in TLR7 responsive mice is RNA and type 1 interferon dependent.

The Risk of Myocardial Infarction in Patients with Systemic Lupus Erythematosus: A Population-based Cohort Study

TNFAIP3 Expression is Regulated by the SLE Associated TT>A Variant

Urine biomarkers for monitoring disease activity in Juvenile Lupus Nephritis. A prospective longitudinal study.

Validation of the Lupus Impact Tracker (LIT), a Patient-Reported Outcome (PRO) tool, in a Longitudinal Study of Systemic Lupus Erythematosus (SLE) Patients

Which Lupus Trial Endpoints Best Reflect Clinical Judgment or Biomarker Improvement?



Patients Congress

Como comenzar un exitoso grupo de apoyo de lupus. Como abogar persuasivamente por el lupus.
Schofield, Kim

Calva y brillante como la luna. Diario de una loba contra el lupus.
AthiÉ, Laura

¿Debería poner atención especial al riesgo cardiovascular?
Eimon, Alicia

¿Cómo llegamos a enfermar? Y qué estrategias podemos usar para sanar.
Lunic, Maria Cristina

Genetic and environmental factors in lupus.
Cardiel, Mario H.

Lupus nephritis: what treatment options are the best for me and how I can help my doctor to better manage it?
Molina, Jose

Lupus y embarazo: la planificación anticipada y el control médico adecuado.
Cervera, Ricard

Management of lupus.
Alarcon, Graciela S.






inc_view_static_content.htm
File: inc_herra_s_related_gallery.htm
Location Map: Discover our Centers in Latin America
Suscribe to our Newsletter
Subscribe and receive all the news in your email.
Contact us
Questions or suggestions please contact Gladel.
inc_panel_right.htm

File: frontend_view_content.htm